Skip to content
Medical Health Aged Care

Engineer-mum turns breastmilk worries into smart device for parents

Monash University 3 mins read
  • Monash University engineers have developed a world-first, device that accurately tracks how much breastmilk a baby drinks - in real time.

  • Perceived insufficient milk supply (PIMS) is one of the leading reasons women stop breastfeeding before six months, despite meeting their baby’s needs.

  • Inspired by her own experience as a new mum, Dr Fae Marzbanrad created the AI-powered monitor - now close to commercialisation.

For countless new mums, one of the hardest parts of breastfeeding isn’t the latch or the logistics - it’s the uncertainty. Is my baby getting enough? Am I making enough? 

Perceived insufficient milk supply (PIMS) is a major reason why women stop breastfeeding before the minimum six months recommended by Australian guidelines.

A large review, published in 2021, found that – amongst breastfeeding mothers – perceived insufficient milk supply (PIMS) is one of the major reasons for discontinued breastfeeding, with approximately 50 per cent of mothers reported PIMS as the reason for stopping breastfeeding.

Now a Monash University researcher has developed a smart device that measures, in real time, how much milk a baby consumes while breastfeeding.

The device, developed by Dr Fae Marzbanrad and her team at the Faculty of Engineering, works by placing a small probe on the baby’s neck while feeding. . A working wireless prototype has been developed and is now close to commercialisation.

The sensor records signals that use AI to instantly measure the amount of milk the baby consumes per feed. 

“My baby wasn’t putting on enough weight, which was a stressful and difficult experience as an overwhelmed new mum,” said Dr Marzbanrad, head of the Biomedical Signal Processing Research Lab at Monash.

“I also found that this was a common experience for other women in my mother’s group. So, I developed a device to solve this problem, and many mums I know are now waiting for it and willing to pay for it.”

In a new pilot study of 24 newborns, the Infafeed monitor successfully showed that it can track newborn feeding accurately, addressing a longstanding gap in neonatal feeding assessment with a non-invasive, AI-powered solution.

“Maternal concern about insufficient milk supply is a major cause of premature cessation of exclusive breastfeeding. The Infafeed monitor provides a non-invasive objective tool for assessing neonatal milk intake, with the potential to reduce unnecessary supplementation, enable early identification of feeding problems, and support breastfeeding continuation,” Dr Marzbanrad said.

The monitor was developed in collaboration with Associate Professor Atul Malhotra, a neonatologist from Monash Department of Paediatrics and Monash Children's Hospital. The researchers believe that, if validated in larger studies, the monitor could enhance breastfeeding support strategies in both clinical and home settings.

“The technology could be particularly beneficial for preterm or low birth weight babies when they transition from gastric tube feeding to breast or bottle feeding, helping them gain weight more effectively while providing parents with accurate data and peace of mind,” Associate Professor Malhotra said.

The work has already generated significant interest among parents and medical professionals eager for a reliable, non-invasive solution to monitor infant feeding.

DOI: 10.5005/jp-journals-11002-0121

MEDIA ENQUIRIES:

Courtney Karayannis, Media and Communications Manager

Monash University

T: +61 408 508 454 or [email protected] 


GENERAL MEDIA ENQUIRIES

Monash Media

P: +61 3 9903 4840

E: [email protected]

For more experts, news, opinion and analysis, visit Monash News.

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 11/07/2025
  • 16:28
The Florey

Harnessing mRNA to prevent and slow Alzheimer’s disease

mRNA Victoria funds 2Floreyprojects to prevent and treat Alzheimer’s disease Key points mRNA Victoria has funded 2 Alzheimer’s disease research projects that could position Victoria as a leader in the development of mRNA-based therapies. Dr Abdel Belaidi will develop an mRNA-based system that crosses the blood-brain barrier and aims to slow or even halt disease progression. Dr Rebecca Nisbet will develop an mRNA vaccine that aims to prevent Alzheimer’s disease from developing. Florey researchers working at the cutting edge of dementia research have received funding from mRNA Victoria to develop treatments and a vaccine for Alzheimer’s disease. Since mRNA vaccines…

  • Medical Health Aged Care
  • 11/07/2025
  • 07:05
Royal Australian College of GPs

GPs urge Tasmanian families to get vaccinated against whooping cough and call for free shots to reduce barriers

The Royal Australian College of GPs (RACGP) is urging Tasmanian families to get vaccinated against pertussis, or ‘whooping cough’ and called on all parties and candidates running in the state election to commit to making the vaccination free for all patients. From 1 January 2024 to April 2025, 1238 whooping cough cases were notified in Tasmania, including 10 infants aged under six months. Most hospitalisations and deaths occur in this group, who are not old enough to have received all vaccine doses. More than 21,000 infections were recorded nationwide last year, compared to just 2450 in 2023, and the National…

  • Contains:
  • General News, Medical Health Aged Care
  • 11/07/2025
  • 07:00
La Trobe University

La Trobe researchers awarded $4.5 million in ARC Future Fellowships

LaTrobe University researchers have secured almost $4.5 million in Federal Government funding to further studies into areas such as immune cell development, Australian history and agriculture. Four researchers received an Australian Research Council (ARC) Future Fellowship 2025. The prestigious Future Fellowships support high quality research in areas of national and international benefit, including in national research priorities. Dr Lisa Mielke, from the School of Cancer Medicine, the La Trobe Institute of Molecular Science (LIMS) and the Olivia Newton-John Cancer Research Institute (ONJCRI), received $1.13 million to identify new molecules for future drug and vaccine development to improve gut health in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.